What alopecia areata looks like on a Black scalp
StatPearls describes alopecia areata as a chronic, immune-mediated disorder affecting hair follicles and nails. The immune system attacks follicles in their growth phase and pushes them out of it early, without permanent damage to the follicle. That is the most important fact here: the hair can come back, even after years.
The classic presentation, per StatPearls, is isolated, smooth, sudden, nonscarring, patchy hair loss on the scalp or any area with hair growth. The AAD adds the detail that decides most home diagnoses: where you have the hair loss, you see no signs of irritation like swelling or discoloration. No scale, no bumps, no color change.
Four findings support it:
- Exclamation-mark hairs. Short broken hairs at the edge of the patch, narrower at the scalp end than at the tip. StatPearls calls this pathognomonic, meaning its presence settles the diagnosis.
- Nail changes. StatPearls puts nail involvement at 10 to 15 percent of patients, the AAD at 10 to 20 percent. Tiny dents, called pitting, are most common, along with lengthwise ridges, a sandpaper texture, and splitting.
- Sensation before the loss. The AAD reports itching, tingling, or burning where hair loss is about to begin.
- Spared white hairs. StatPearls notes white hair is often spared, so early disease can look like sudden greying.
It is not confined to the scalp. StatPearls lists the beard, eyebrows, eyelashes, and extremities. A band of loss around the back of the head is the ophiasis pattern, total scalp loss is alopecia totalis, total body loss is alopecia universalis.
What this looks like under a dermatoscope on Black scalps is barely documented. A 2025 Journal of Drugs in Dermatology study by Pyles and colleagues reviewed trichoscopic images from 10 Black patients at an academic hair loss clinic, reporting peripilar hyperpigmentation, follicular hypopigmentation, diffuse erythema, uninterrupted honeycomb patterns, and perifollicular scale as novel in this population. Ten patients is a small series. The authors' conclusion is that these features should lower the threshold for spotting a second, coexisting alopecia.
Black women have higher odds of alopecia areata
Thompson and colleagues published the clearest number on this in 2018 in the Journal of Investigative Dermatology Symposium Proceedings, analyzing self-reported alopecia areata across 63,960 women in the Nurses' Health Study (418 cases) and 88,368 in Nurses' Health Study II (738 cases). The multivariate-adjusted odds ratio for Black women compared with white women was 2.72 (95% CI 1.61 to 4.61) in the first cohort and 5.48 (95% CI 4.10 to 7.32) in the second. Hispanic women in the second cohort had an odds ratio of 1.94 (95% CI 1.24 to 3.02) compared with non-Hispanic white women.
Read those numbers with their design attached. Diagnoses were self-reported, the analysis was cross-sectional, so it measures odds rather than incidence, and both cohorts are nurses. StatPearls states the same direction plainly: alopecia areata occurs more often among Asian, Black, and Hispanic patients. For scale, it puts lifetime risk in the general population at 2 percent, with a mean onset age of 36 in women, and a 2020 Journal of the American Academy of Dermatology meta-analysis of 94 studies put pooled global prevalence at 2.11 percent.
Carry that into the exam room. When a Black woman brings hair loss to a clinician, the reflex answer is her hair care. The published odds say alopecia areata belongs on the list before anyone reaches a conclusion about braids.
Areata, CCCA, or traction alopecia: telling the three apart
These are three diseases with three mechanisms, three patterns, and three outcomes. Two of them are the diagnoses Black women usually get. The third is the one that gets missed.
| Alopecia areata | CCCA | Traction alopecia | |
|---|---|---|---|
| Where it starts | Anywhere hair grows. Often one patch on the scalp or beard. | The crown or vertex, then spreads outward in a circle. | Tension-bearing areas: hairline, temples, in front of the ears. |
| Shape | A smooth round or oval patch with a defined edge. | A widening central zone of thinning. | A receding band, often with a fringe left at the edge. |
| How fast | Weeks. | Years. | Years, tracking the styling. |
| The skin inside it | Normal. No swelling, no discoloration, no scale. | Inflamed. Tenderness, itching, burning, follicle openings vanish. | Broken hairs, hair casts, sometimes folliculitis. |
| Does it scar? | No. The follicle survives. | Yes. The loss is permanent. | Not early. Yes if the tension continues. |
| Telltale sign | Exclamation-mark hairs at the border, nail pitting. | Loss of follicular openings across the crown. | Loss that maps to where the style pulls. |
| Cause | Autoimmune. | Multifactorial, unclear. Runs in families. | Mechanical tension on the follicle. |
| Can it regrow? | Yes, at any stage. | Not from scarred scalp. | Yes early. No once scarred. |
CCCA. StatPearls describes central centrifugal cicatricial alopecia as patches of permanent hair loss on the vertex or crown that spread centrifugally, with signs and symptoms of inflammation, and calls it the most common scarring alopecia among middle-aged women of African descent, with reported prevalence of 2 to 7 percent. Scarring is the dividing line: once the follicle is replaced by connective tissue, no drug brings it back. Our guide is at hair loss in Black women and CCCA.
Traction alopecia. StatPearls describes hair loss along tension-bearing areas, typically the temples and in front of the ears, with early folliculitis, hair casts, and broken hairs. It calls the course biphasic: early disease is nonscarring and reversible, chronic disease becomes permanent scarring alopecia. A study of African American girls aged 5.4 to 14.3 cited there found signs of it in 18 percent. Our guide is at traction alopecia in Black women.
You can have more than one. Traction alopecia at the hairline does not protect you from an autoimmune patch at the crown. If a new patch does not fit the diagnosis you already carry, say so out loud. StatPearls also lists androgenetic alopecia, trichotillomania, tinea capitis, and secondary syphilis in the differential.
Treatment, and the pigment risk that matters on Black skin
One or two patches, under a year old: waiting is a real option. The AAD says a dermatologist may recommend a wait-and-see approach, because many people regrow hair without treatment. Waiting is a decision, and it comes with a follow-up date.
Injected corticosteroids are the workhorse for patchy disease. StatPearls describes triamcinolone acetonide at 5 to 10 mg/mL injected every 4 to 6 weeks, producing localized regrowth in 60 to 67 percent of patients, with therapy stopped if nothing changes by 6 months. The AAD cites a study of 127 patients in which more than 80 percent of those injected regrew at least half their hair within 12 weeks, and calls injections the most effective treatment for a few patches.
Topical steroids and minoxidil fill in around the injections. StatPearls names betamethasone dipropionate 0.05 percent applied daily about 1 cm past the border of the patch, mainly for children and people who cannot tolerate injections, stopped at 3 months without improvement. The AAD positions minoxidil as the drug that keeps hair that has already regrown.
Contact immunotherapy is for extensive disease. A contact allergen, diphenylcyclopropenone or squaric acid dibutyl ester, is applied weekly to provoke a controlled mild dermatitis. The AAD reports success rates from 17 to 75 percent and warns that missed appointments can undo regrowth. A meta-analysis cited in StatPearls found regrowth in 74.6 percent of patchy cases against 54.4 percent of totalis and universalis cases.
JAK inhibitors changed what severe disease can expect. Three are FDA-approved, and the Drugs@FDA record carries the dates: baricitinib for severe disease in adults on June 13, 2022, ritlecitinib for adults and adolescents 12 and older on June 23, 2023, and deuruxolitinib for adults on July 25, 2024.
The trial results, all measured as a SALT score of 20 or less, meaning at least 80 percent of the scalp covered:
- Baricitinib (BRAVE-AA1 and BRAVE-AA2, 654 and 546 adults, 2022): 38.8 and 35.9 percent on the 4 mg dose reached it at week 36, against 6.2 and 3.3 percent on placebo.
- Ritlecitinib (ALLEGRO, 718 patients aged 12 and up, 2023): 31 percent on the highest regimen tested, a 200 mg loading dose followed by 50 mg, and 23 percent on the 50 mg dose alone at week 24, against 2 percent on placebo.
- Deuruxolitinib (THRIVE-AA1, 2024): at week 24, 29.6 percent at 8 mg twice daily and 41.5 percent at 12 mg twice daily, against 0.8 percent on placebo.
Two things belong beside those percentages. StatPearls notes the FDA boxed warning covering serious infections, death, malignancy, major adverse cardiovascular events, and thrombosis, and that continued use is generally required to hold the benefit. And in ALLEGRO, 27 of 718 participants (4 percent) were Black or African American, in a disease that is more common in Black patients.
What to expect: regrowth, relapse, and the calendar
StatPearls reports that 34 to 50 percent of people with patchy hair loss recover spontaneously within a year. The AAD says with treatment some regrowth is possible in 6 weeks, though full regrowth takes months. The AAD says regrown hair may come back white or blond and finer than before, and that this is usually temporary. A patch of fine white hair is the follicle restarting, not a failed treatment.
The harder numbers sit next to those. StatPearls states that most patients experience recurrence and fewer than 10 percent recover completely, that roughly 10 percent of patchy cases progress to alopecia totalis or universalis, and that relapse occurs within a year in about a third of patients who responded. Markers of a rougher course: childhood diagnosis, an ophiasis distribution, family history, severe disease, duration beyond a year, nail dystrophy, atopy, or another autoimmune condition.
StatPearls links alopecia areata with thyroid disease, vitiligo, psoriasis, lupus erythematosus, and atopic dermatitis, and says current evidence does not support routine screening unless the history suggests one of them. Keep the primary care appointment and name the diagnosis there.
Wigs, coverage, and the part nobody budgets for
The AAD lists wigs, hairpieces, and scalp prostheses among the standard options for covering hair loss, and defines a scalp prosthesis as a custom-fitted wig, also called a hair prosthesis or cranial prosthesis. That vocabulary matters on paperwork. The National Alopecia Areata Foundation states the coverage reality in its advocacy agenda: most insurance carriers do not provide coverage for a cranial prosthetic under the pretext that alopecia areata is a cosmetic condition. NAAF is pursuing federal legislation to reclassify wigs as durable medical equipment eligible for Medicare, plus state bills.
One channel is written down federally. IRS Publication 502 states that you can include in medical expenses the cost of a wig purchased upon the advice of a physician for the mental health of a patient who has lost all of their hair from disease. Read the qualifier honestly: it is written for total hair loss, not a single patch. If it applies, get the recommendation in writing and keep the receipt, because that is what makes it an eligible FSA or HSA expense.
Two AAD instructions that cost nothing. Protect exposed scalp from the sun, because thinning areas burn: a hat, a wig, or broad-spectrum SPF 30 or higher reapplied every two hours. And be gentle with what is left: a soft-bristled brush and wide-tooth comb, no dyes or fragranced products, air drying instead of heat, and loose styles rather than tight ponytails.
When to see a dermatologist
Book the visit when:
- A smooth bald patch appeared over weeks rather than years, anywhere on your body.
- The patch is spreading, a second one has appeared, or the loss has reached your eyebrows, eyelashes, or beard.
- Your nails have developed pitting, ridges, a sandpaper texture, or splitting.
- You have been treated for traction alopecia or CCCA and a new patch does not fit that pattern.
- More than half your scalp is involved. That is the level of loss the JAK inhibitor trials enrolled, and the point at which contact immunotherapy and systemic treatment enter the conversation.
Bring the photographs and the date the patch appeared, and ask three questions: is this scarring or nonscarring, what steroid concentration are you injecting, and when do we discuss systemic treatment. You can find a Black dermatologist in our directory, including clinicians who list hair loss and skin of color as a practice focus.
Frequently asked questions
Is alopecia areata the same as traction alopecia? ▼
No. Alopecia areata is an autoimmune attack on the follicle that produces smooth round patches over a few weeks, anywhere hair grows. Traction alopecia is mechanical damage from pulling, appearing along tension-bearing areas such as the temples and in front of the ears. See our guide to traction alopecia in Black women.
Will my hair grow back after alopecia areata? ▼
Often, yes. The follicle is not destroyed, which is what separates this from scarring alopecia. StatPearls reports that 34 to 50 percent of people with patchy disease regrow hair within a year with no treatment, and that most people have recurrences while fewer than 10 percent recover completely.
Why do I have bald patches but my scalp looks completely normal? ▼
That is the diagnosis, not a contradiction. The AAD notes that in alopecia areata you see no signs of irritation such as swelling or discoloration where the hair is missing. Scale, tenderness, bumps, or follicle openings that have disappeared point elsewhere, most often to CCCA or a fungal infection.
Can I have alopecia areata and CCCA at the same time? ▼
Yes. They are unrelated diseases and having one does not exclude the other. The 2025 trichoscopy study of Black patients with alopecia areata frames its purpose as lowering the threshold for diagnosing coexisting alopecias. If you carry a CCCA diagnosis and a new patch behaves differently, say that in the room. Our CCCA guide covers the scarring side.
Are JAK inhibitors worth it for alopecia areata? ▼
They are approved for severe disease, not for one small patch. In the phase 3 baricitinib trials, 38.8 and 35.9 percent of patients on the 4 mg dose had 80 percent or more scalp coverage at week 36, against 6.2 and 3.3 percent on placebo. StatPearls notes the class boxed warning covering serious infections, death, malignancy, major cardiovascular events, and thrombosis, and that ongoing use is needed to hold the result.
Will insurance pay for a wig if I have alopecia areata? ▼
Usually not, according to the National Alopecia Areata Foundation, which says most carriers deny coverage for a cranial prosthetic on the grounds that alopecia areata is cosmetic. Separately, IRS Publication 502 allows a wig as a medical expense when a physician advises it for the mental health of a patient who has lost all of their hair from disease, which can make it FSA or HSA eligible.
